Dartmouth College

Corixa Corporation

Bristol-Myers Squibb Compnay

University of Massachusetts

Other

Teresa M Foy

Randolph J Noelle

Robert A Henderson

Jeffrey A Ledbetter

Alejandro A Aruffo

Tongtong Wang

Davin C Dillon

Jennifer L Mitcham

Darrick Carter

Jiangchun Xu

Thomas S Vedvick

Yasir A W Skeiky

Patricia Dianne McNeill

Raymond L Houghton

Gary R Fanger

Marc W Retter

Susan L Harlocker

Michael D Kalos

Yuqiu Jiang

Aijun Wang

John A Stolk

Samuel X Li

Craig H Day

William T Hepler

Carlota Vinals Y De Bassols

Fiona H Durie

Yoshihiro Watanabe

Madeleine Joy Meagher

John Hural

Dale L Greiner

Aldo A Rossini

John P Mordes

David C Parker

Ta Deng

Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

Compositions and methods for the therapy and diagnosis of lung cancer

Methods for inducing antigen-specific T cell tolerance are disclosed. The methods involve contacting a T cell with: 1) a cell which presents antigen to the T cell, wherein a ligand on the cell interacts with a receptor on the surface of the T cell which mediates contact-dependent helper effector function; and 2) an antagonist of the receptor on the surface of the T cell which inhibits interaction of the ligand on the antigen presenting cell with the receptor on the T cell. In a preferred embodiment, the cell which presents antigen to the T cell is a B cell and the receptor on the surface of the T cell which mediates contact-dependent helper effector function is gp39. Preferably, the antagonist is an anti-gp39 antibody or a soluble gp39 ligand (e.g., soluble CD40). The methods of the invention can be used to induce T cell tolerance to a soluble antigen or to an allogeneic cell. The methods of the invention can also be used to induce tolerance in cases of bone marrow transplantation and other organ transplants and to inhibit graft-versus-host disease.

Methods for reducing T cell responsiveness to an autoantigen with anti-gp39 antibodies and antigen presenting cells

Methods of suppressing a humoral immune response to a thymus-dependent (TD) antigen are disclosed. The methods involve administering to a subject a TD antigen with an antagonist of a molecule which mediates contact-dependent helper effector functions. In a preferred embodiment, the antagonist is an antagonist of gp39. Primary and secondary humoral immune responses can be suppressed and suppression is prolonged.

Methods of inhibiting IgE responses to thymus-dependent antigens with the anti-gp39 antibody MR1

Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.

Prostate-specific polynucleotide compositions

Compositions and methods for the therapy and diagnosis of prostate cancer

A method of treating graft-vs-host diseases by administration of bone marrow and an anti-gp39 antibody specific to human gp39 is provided.

Method of treating graft-versus-host disease with anti-GP39 antibodies and bone marrow cells

Method for prolonged suppression of humoral immune response to a

Antibodies that bind a protein gp39 (also referred to as CD40 ligand) are disclosed. Preferably, the antibodies are monoclonal antibodies of an IgG1 isotype and bind human gp39. In a preferred embodiment, an antibody of the invention binds an epitope recognized by a monoclonal antibody 24-31, produced by a hybridoma 24-31 (ATTC Accession No. HB11712) or binds an epitope recognized by a monoclonal antibody 89-76, produced by a hybridoma 89-76 (ATCC Accession No. HB 11713). Pharmaceutical compositions comprising the antibodies of the invention are also disclosed. The antibodies of the invention are useful for inhibiting B cell proliferation and differentiation, T cell responses and for inducing T cell tolerance. Nucleic acid molecules encoding anti-gp39 antibodies, or portions thereof, as well as expression vectors and host cells incorporating said nucleic acid molecules, are also encompassed by the invention.

Methods of inducing T cell non-responsiveness to transplanted tissues

Methods of inducing T cell unresponsiveness to bone marrow with gp39

Antibodies that bind a protein gp39 (also referred to as CD40 ligand) are disclosed. Preferably, the antibodies are monoclonal antibodies of an IgG1 isotype and bind human gp39. In a preferred embodiment, an antibody of the invention binds an epitope recognized by a monoclonal antibody 24-31, produced by a hybridoma 24-31 (ATTC Accession No. HB11712) or binds an epitope recognized by a monoclonal antibody 89-76, produced by a hybridoma 89-76 (ATCC Accession No.HB11713). Pharmaceutical compositions comprising the antibodies of the invention are also disclosed. The antibodies of the invention are useful for inhibiting B cell proliferation and differentiation, T cell responses and for inducing T cell tolerance. Nucleic acid molecules encoding anti-gp39 antibodies, or portions thereof, as well as expression vectors and host cells incorporating said nucleic acid molecules, are also encompassed by the invention.

Anti-GP39 antibodies

Growing community of inventors

Federal Way, WA, United States of America

Teresa M Foy